Tag Archive for: TG Therapeutics

MS

Neuraxpharm pays US$650m for MS drug commercialisation

TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.

Read more